The Ministry of Health has approved Jardiance (Boehringer Ingelheim and Lilly) for patients with chronic kidney disease.

Boehringer Ingelheim and Lilly Alliance announced this Wednesday that the Department of Health has approved funding for the drug Jardins (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), which has been shown to reduce the risk of kidney disease progression or death from cardiovascular disease, as well as also the risk of hospitalization for any reason.

As explained at the press conference, this is a drug that has already been used in Spain to treat patients with type 2 diabetes mellitus and heart failure. It will be available for new use in the ERC starting this Friday.

Hospitalizations account for one-third to one-half of total health care costs for people with CKD. In total, it affects 1 in 7 people in Spain, which represents 15% of the population.

(Chronic kidney disease, silent until the kidneys almost stop working.)

Because the initial phases of the disease are asymptomatic, many people may not realize they have it. In fact, it is assumed that 2 out of 3 patients are not diagnosed.

In addition, CKD doubles the risk of hospitalization and is one of the leading causes of death worldwide. In Spain, treatment of the most advanced stages of chronic kidney disease requires almost 3% of National Health System (NHS) spending on healthcare and 4% from specialized inpatient care.

Kidney diseases

People with chronic kidney disease experienceeducation quality of life in advanced stages of the disease, often due to the heavy burden of symptoms and treatments.

Likewise, depression It affects up to one-third of the total diagnosed kidney population and is most often diagnosed in people with advanced kidney disease.

Early diagnosis of chronic kidney disease is an appropriate and cost-effective intervention for the NHS. Although we are talking about a silent disease, we know the risk factors that increase the likelihood of developing it.

“This Early approach may reduce the risk of worsening kidney function kidney failure and hospitalizations,” said Dr. José Luis Gorriz, head of the nephrology department at the University of Valencia Clinical Hospital.